Publication Beamlines Strategic Pillar
(2022). Nanoparticle platform for antibody and vaccine delivery. Patent Number: PT3661968T.
(2021). MODELING TEST. Patent Number: PT3311169T.
(2014). ANTIBODIES AGAINST BRADICININE B1 RECEIVER LIGANDS. Patent Number: AR090352A1.
(2018). Anti-hemagglutinin antibodies and methods of use. Patent Number: IL263320A.
(2023). Anti-bcma antibodies, bispecific antigen binding molecules that bind bcma and cd3, and uses thereof. Patent Number: IL257468B2.
(2017). ANTI-BCMA ANTIBODIES (CELL MATURATION ANTIGEN B), BINDING SPECIFIC MOLECULES THAT JOIN BCMA AND CD3 (AGGREGATE DETERMINANT 3), AND USES OF THESE. Patent Number: AR105724A1.
(2021). Stable heterodimeric antibody design with mutations in the fc domain. Patent Number: PT2773671T.
(2015). Anti-hemagglutinin antibodies and methods of use. Patent Number: IL238684A0.
(2025). Anti-bcma antibodies, bispecific antigen binding molecules that bind bcma and cd3, and uses thereof. Patent Number: IL320478A.
(2022). ANTIBODY EPITOPE. Patent Number: PT3311171T.
(2023). Novel tnf structure for use in therapy. Patent Number: PT3311168T.
(2015). ANTIHEMAGLUTININE ANTIBODIES AND METHODS OF USE. Patent Number: AR093446A1.
(2020). ANTI-BCMA ANTIBODIES, BIESPECIFIC ANTIGEN BINDING MOLECULES THAT BIND BCMA AND CD3, AND THEIR USES. Patent Number: PT3337824T.
(2025). Anti-bcma antibodies, bispecific antigen binding molecules that bind bcma and cd3, and uses thereof. Patent Number: IL298041B2.
(2015). Novel TNFa structure for use in therapy. Patent Number: GB201510758D0.